No Data
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating
Maxim Group analyst Jason McCarthy maintains $Gain Therapeutics(GANX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 24.0% and a total average return of -21.2%
Optimistic Outlook for Gain Therapeutics Amid Progress of GT-02287 and Successful Financing
Gain Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright analyst Ram Selvaraju maintains $Gain Therapeutics(GANX.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 39.8%
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and Gain Therapeutics (GANX)